Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Sponsor: Kivu Bioscience Inc.
Summary
This is a 2-part, first-in-human, open-label study to determine the safety and tolerability of KIVU-107, a PTK7-directed antibody-drug conjugate, in participants with locally advanced or metastatic solid tumors.
Official title: A Phase 1 Dose-Finding and Dose-Expansion Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
76
Start Date
2025-11-13
Completion Date
2030-03-31
Last Updated
2026-03-10
Healthy Volunteers
No
Conditions
Interventions
KIVU-107
KIVU-107 will be administered IV.
Locations (4)
Kivu Trial Site
Sydney, New South Wales, Australia
Kivu Trial Site
Brisbane, Queensland, Australia
Kivu Trial Site
Adelaide, South Australia, Australia
Kivu Trial Site
Geelong, Victoria, Australia